Bruker Introduces maXis HD Ultra-High Resolution QTOF
At the 12th Human Proteome Organization World Congress (www.hupo.org/2013), Bruker completed its series of High-Definition (HD) QTOF systems introductions with the launch of its new flagship maXis HD ultra-high resolution (UHR) QTOF mass spectrometer. With its best-in-class full sensitivity resolution (FSR) greater than 75,000, the new maXis HD is ideally suited for top-down proteomic analyses and the characterisation of biopharmaceuticals.
The novel maXis HD features a new High-Definition Collision (HDC) cell which enables its record-breaking full sensitivity mass resolution, as well as accurate mass capabilities well beyond all competing QTOF As a result of its extreme sensitivity broad mass-transfer ion optics and the fastest available 50 Gbit/s sampling technology, a dynamic range of five orders of magnitude is achieved in one second of LC time. High dynamic range at high speed is a prerequisite for high-resolution detection of low-abundance compounds in sharp UHPLC peaks and permits direct identification and quantitation without re-runs.
The maXis HD offers break-through analytical performance for applications in top-down proteomics and in biopharmaceutical compound analysis, and the instrument excels in the analysis of intact proteins and antibodies. For antibody subunits, it can provide unprecedented insight into antibody structures via its ultra-high resolution at high mass with baseline discrimination of isotope envelopes at excellent mass accuracy.
The maXis HD also delivers a new confidence level in the fast, high-resolution, accurate mass screening, identification and quantification of small molecules. The novel HDC cell and HD detection technology translate directly into enhanced dynamic range and extreme sensitivity down to very low masses at UHPLC speed, a precondition for one-shot plug and play acquisitions in multi-target applications. The recording-breaking full sensitivity resolution in combination with the Bruker proprietary, real-time SmartFormula 3D software makes the maXis HD the tool of choice for true unknown screening and the ab initio determination of elemental composition at UHPLC speed and throughput.
Dr Michael Schubert, President of the Bruker Daltonics Life-Science & Clinical Division, stated: “With these performance features we believe that the new maXis HD delivers the fastest time-to-success for customers across a broad applications portfolio, covering small molecule identification and characterisation; food, forensic and environmental screening; metabolomics; as well as top-down proteomics and antibody analysis."
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance